Placing of £1,000,000
CRISM Therapeutics Corporation has successfully raised £1,000,000 through an oversubscribed placing of 11,111,112 new ordinary shares at 9 pence per share, with each share receiving a warrant exercisable at 15 pence. The net proceeds will fund the company's MHRA-approved Phase 2 clinical trial of irinotecan-ChemoSeed for glioblastoma, covering sterilisation, quality control, clinical trial costs, and operational expenses, with first patient dosing anticipated in Q1 2026. A separate retail offer to raise up to £100,000 is also planned. Directors participated in the placing, acquiring shares and warrants, which has been deemed fair and reasonable by the company's nominated adviser.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Placing of £1,000,000
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical stage company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce that it has successfully raised £1,000,000 by way of an oversubscribed placing of 11,111,112 new ordinary shares of no par value each in the Company ("Placing Shares") at a price of 9 pence per share (the "Issue Price") (the "Placing"). The Placing Shares each have an attaching grant of warrants ("Warrants") on a one for two basis, exercisable at a price of 15 pence per ordinary share, and expiring on 31 December 2026.
The Placing Shares will represent approximately 21.76% of the Company's enlarged issued share capital following the Placing. The Issue Price represents a discount of approximately 18.18 per cent. to the closing mid-market price of 9 pence per ordinary share on 09 December 2025.
The Placing was undertaken by the Company's broker, SP Angel Corporate Finance LLP.
The Company values its retail shareholder base and believes that it is appropriate to provide existing retail and other shareholders the opportunity to purchase shares at the Issue Price. The Company intends to carry out a separate retail offer to raise further gross proceeds of up to £100,000 via the BookBuild Platform (the "Retail Offer"). A further announcement will be made shortly regarding the Retail Offer and its terms.
Highlights of the Placing:
- Completion of Placing raising £1,000,000 through the issue of 11,111,112 Placing Shares at 9 pence per share
- The net proceeds of the Placing will allow the Company to progress its MHRA approved Phase 2 open label clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma. Specifically, funds will be used for:
o Sterilisation and lot release of GMP of ChemoSeed
o QP, quality and audit fees
o Clinical trial costs - ongoing fees, dose escalation seeking efficacy signal in recurrent patients
o Ongoing operational costs
- A separate retail offer to existing holders will be launched shortly
CRISM Executive Chairman, Andrew Webb, said: "We are delighted by the support of new and existing shareholders in this oversubscribed Placing, which will enable the Company to progress into patient dosing in its Phase 2 clinical trial of irinotecan-ChemoSeed in glioblastoma and to reach the important inflexion point of establishing an efficacy signal in patients with recurrent disease, subject to patient recruitment. We look forward to first patient dosing in Q1 2026."
Rationale for the Placing
The Placing will enable the Company to progress its Phase 2 open-label clinical trial, with first patients expected to be dosed in Q1 2026. The open label trial design allows for ongoing safety and efficacy monitoring.
Directors' Participation and Related Party Transactions
The Directors of the Company have participated in the Placing, details of which are in the table below:
| Director | Number of Placing Shares subscribed for | Number of ordinary shares held immediately following Admission | % interest in ordinary shares immediately following Admission |
|---|---|---|---|
| Andrew Webb | 916,667 | 7,297,190 | 14.29% |
| Chris McConville | 83,333 | 4,992,033 | 9.77% |
| Gerry Beaney | 111,111 | 268,793 | 0.53% |
The participation of Andrew Webb, Chris McConville and Gerry Beaney in the Placing (including the issue of the Warrants referred to below) constitutes related party transactions for the purposes of Rule 13 of the AIM Rules for Companies. As all of the Directors are participating in the Placing, there is no independent director for the purpose of the related party transaction as stipulated by the AIM Rules for Companies.
The Company's nominated adviser, SP Angel Corporate Finance LLP, considers that the Directors' participation in, and the terms of, the Placing is fair and reasonable in so far as CRISM's shareholders are concerned.
Warrants
The Company will issue participants of the Placing with one Warrant for every two Placing Shares. As a result, 5,555,551 Warrants will be issued to the placees. Each Warrant will provide the holder with the right to one new ordinary share on its exercise. The Warrants will be exercisable at a price of 15 pence until 31 December 2026.
Andrew Webb, Chris McConville and Gerry Beaney, have been issued with 458,333, 41,666 and 55,555 Warrants respectively, as a result of their participation in the Placing.
Admission and Total Voting Rights
Application has been made to the London Stock Exchange for admission of the Placing Shares ("Admission"). It is expected that Admission will become effective and that trading will commence in the Placing Shares at 8.00 a.m. on or around 15 December 2025, or such later date as may be agreed between the Company and SP Angel. The Placing Shares will rank pari passu with the Company's existing ordinary shares.
Following the issue of the Placing Shares, the total issued share capital of the Company will consist of 51,072,934 ordinary shares. The Company does not hold any ordinary shares in treasury. Therefore, the total number of voting rights in the Company is 51,072,934 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Company's LEI is 213800XFW6MKVCHHPW88.
Dealings by Persons Discharging Managerial Responsibilities
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Andrew Webb 2) Gerald Beaney 3) Chris McConville |
| 2 | Reason for the notification | |
| a) | Position/status | 1) Executive Chairman 2) Non-Executive Director 3) Chief Scientific Officer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | CRISM Therapeutics Corporation |
| b) | LEI | 213800XFW6MKVCHHPW88 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares with no par value |
| Identification code | ISIN: VGG042401262 | |
| b) | Nature of the transaction | Purchase of shares |
| c) | Price(s) and volume(s) | Director/PDMR Price (£) Volume Andrew Webb 0.09 916,667 Gerald Beaney 0.09 111,111 Chris McConville 0.09 83,333 |
| d) | Aggregated information | |
| - Aggregated volume | N/A | |
| - Price | N/A | |
| e) | Date of the transaction | 10 December 2025 |
| f) | Place of the transaction | Outside a trading venue |
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Andrew Webb 2) Gerald Beaney 3) Chris McConville |
| 2 | Reason for the notification | |
| a) | Position/status | 1) Executive Chairman 2) Non-Executive Director 3) Chief Scientific Officer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | CRISM Therapeutics Corporation |
| b) | LEI | 213800XFW6MKVCHHPW88 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares with no par value |
| Identification code | ISIN: VGG042401262 | |
| b) | Nature of the transaction | Issue of warrants |
| c) | Price(s) and volume(s) | Director/PDMR Exercise Price Volume Andrew Webb £0.15 458,333 Gerald Beaney £0.15 55,555 Chris McConville £0.15 41,666 |
| d) | Aggregated information | |
| - Aggregated volume | N/A | |
| - Price | N/A | |
| e) | Date of the transaction | 10 December 2025 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.